pp-228 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Plaque Psoriasis & Systemic Lupus Erythematosus (SLE) / Clinical stage: Phase 3 / Modality: Small molecule tyrosine kinase-2 (TYK2) inhibitor / Mechanism & Target: Selective oral TYK2 inhibitor / Route & form: Oral / Differentiation: Leading skin clearance in psoriasis (65% PASI90 at Wk24)
Manufacturer #39435
| Clinical-stage biopharmaceutical company focused on immune-mediated inflammatory diseases. Develops selective oral small molecules targeting autoimmune signaling pathways. Advances precision therapies through late-stage global Phase 3 clinical programs. |
None